Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
EAP criteria for other products
Exceptional Access criteria on record are for Brand(s): Dupixent; DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen, — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen,
300 mg/ 2mL prefilled syringe and prefilled pen
Effective Date: May 17, 2023
Initiation Criteria:
For the treatment of severe asthma in patients meeting the following criteria;
1. Patient is aged 6 years old or older; AND
2. Dupilumab is being used as an add-on maintenance therapy; AND
3. Patients 6 to 11 years of age with a type 2 or eosinophilic phenotype and a
documented blood eosinophil count equal to or greater than 150 cells/µL within the
past 12 months
OR
Patients 12 years of age or older with a type 2 or eosinophilic phenotype and a
documented blood eosinophil count equal to or greater than 150 cells/µL within the
past 12 months and/or has oral corticosteroid (OCS) dependent asthma; AND
60
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and
prefilled pen)
4. Asthma is inadequately controlled using optimal treatment.
i) For patients 6 to 11 years of age, this is defined as high dose inhaled
corticosteroids (ICS) (greater than or equal to 400 mcg fluticasone
priopionate daily or equivalent) alone OR medium- to high dose ICS plus 1
controller (e.g. a long-acting beta-agonists) AND experiencing at least one
severe exacerbation (defined as having been treated with a systemic
corticosteroid, hospitalized, or having visited an emergency department for
worsening asthma) in the past 12 months
ii) For patients 12 years and older, this is defined as using high dose ICS
(greater than or equal to 500 mcg of fluticasone propionate or equivalent
daily), and 1 or more additional asthma controller(s) (e.g., LABAs)1
5. Patient is not using any other biologics to treat asthma; AND
6. A baseline assessment of asthma symptom control using a validated asthma control
questionnaire must be completed prior to initiation of dupilumab treatment.
7. Request is submitted by a specialist in respirology, or allergy/clinical immunology, or
by a physician with expertise in the treatment of asthma, unless the request
confirms that the patient does not have access to such specialists, in which case the
request may be submitted by an authorized prescriber.
1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately
controlled if they have worsening of asthma resulting in administration of systemic
corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the
past 12 months
Renewal criteria:
Renewals will be considered on a case-by-case basis for patients 6 years of age or older
with type 2 or eosinophilic asthma who do not meet any of the following
discontinuation/stopping criteria:
61
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and
prefilled pen)
• Patient’s 12-month follow-up asthma control questionnaire score using the same
validated asthma control questionnaire completed at baseline does not show
improvement, such as a decrease of less than 0.5 points on the ACQ or an increase of
less than 3 points on the ACT;
• Patient’s subsequent asthma control questionnaire scores have not been maintained at
the score seen following the first 12-months of therapy;
• The number of clinically significant exacerbations defined as worsening of asthma
resulting in administration of systemic corticosteroids, an emergency room visit or
hospitalization, has increased within the previous 12 months.
Renewals will be considered on a case-by-case basis for patients 12 years of age or older
on maintenance treatment with OCS dependent asthma who do not meet any of the
following stopping criteria:
• there has been no decrease in the OCS dose in the first 12 months of treatment
• the reduction in the dose of OCS achieved after the first 12 months of treatment is not
maintained or improved subsequently
Approval duration of initial and renewals: 1 year
62
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 60, record 40, corpus 2025-01-01; name match only, not an eligibility decision
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
EAP criteria for other products
Exceptional Access criteria on record are for Brand(s): Dupixent; DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and
prefilled pen)
Effective date: May 6, 2021
Updated: December 3, 2021 and December 1, 2022
Updated: April 28, 2023
Initiation Criteria
For the treatment of moderate to severe atopic dermatitis in patients meeting the all the
following criteria;
1. 12 years of age or older; AND
2. Diagnosed with moderate-to-severe atopic dermatitis (AD) by the Eczema Area and
Severity Index (EASI) score equal to or greater than 16 points and the Investigators
(Physician) Global Assessment score of 3 to 4; AND
3. Failure to maintain adequate control of their dermatitis with maximally tolerated medical
topical therapies for AD combined with phototherapy (where available); (Note 1 and 2)
AND
4. Failure to maintain adequate control of their dermatitis with maximally tolerated medical
topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators
(methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine). (Note 1 and 2).
5. Dupilumab is prescribed by a dermatologist, allergist, pediatrician or clinical
immunologist, or in consultation with one of these specialists. (Please include the
consult note with the EAP application.)
Exclusion Criteria:
1. Dupilumab will not be funded if it is used in combination with phototherapy or any
immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor
treatment) for treatment of AD.
Notes:
1. For each treatment used, provide documentation of refractory disease and/or
intolerance (including a description of the adverse effect and severity of reaction). If a
patient is deemed to be ineligible or contraindicated to receive the treatment, provide
the reason(s) for their ineligibility.
111
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml Injection solution
2. An adequate trial for patients with AD who undergo therapy with phototherapy,
methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine is defined as
follows:
• For phototherapy: the typical duration would be considered 12 weeks (3 times per
week).
• For methotrexate: an adequate trial would be 10 mg to 20 mg per week for 12
weeks.
• For cyclosporine: an adequate trial would be 2.5 mg/kg to 5 mg/kg per day for 12
weeks.
• For mycophenolate mofetil: an adequate trial would be 1 g twice daily for 12
weeks.
• For azathioprine: an adequate trial would be 1.5 to 2.5 mg/kg/day for 12 weeks.
3. The concurrent use of dupilumab used in combination with other biologics used for
other conditions will be considered on a case-by-case basis.
Renewal Criteria:
First renewal:
Renewal of funding will be considered in patients with documentation of benefit from
treatment. Benefit from treatment is defined as a 75% or greater improvement from
baseline in the Eczema Area and Severity Index (EASI) score (EASI-75) within six months
of treatment initiation.
Subsequent renewals:
Subsequent renewal of funding will be considered in patient who maintain the 75% or
greater improvement in EASI-75 score response from baseline.
Duration of Approval for initial requests: 6 months
Duration of Approval for first and second renewal: 6 months
Duration of Approval for 3rd and subsequent renewals: 1 year
Recommended dose:
Adults: An initial dose of 600 mg followed by 300 mg every other week.
Refer to the product monograph for dosing in adolescents 17 year of age and younger.
112
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 111, record 69, corpus 2025-01-01; name match only, not an eligibility decision
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Dupilumab: not an ODB benefit — Exceptional Access criteria on file (2 indications). EAP application required.
ODB status: not listed in this extract
Write on the script: Exceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗)
Not listed in the Ontario formulary extract (2026-09-22).
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and
prefilled pen)
Effective date: May 6, 2021
Updated: December 3, 2021 and December 1, 2022
Updated: April 28, 2023
Initiation Criteria
For the treatment of moderate to severe atopic dermatitis in patients meeting the all the
following criteria;
1. 12 years of age or older; AND
2. Diagnosed with moderate-to-severe atopic dermatitis (AD) by the Eczema Area and
Severity Index (EASI) score equal to or greater than 16 points and the Investigators
(Physician) Global Assessment score of 3 to 4; AND
3. Failure to maintain adequate control of their dermatitis with maximally tolerated medical
topical therapies for AD combined with phototherapy (where available); (Note 1 and 2)
AND
4. Failure to maintain adequate control of their dermatitis with maximally tolerated medical
topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators
(methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine). (Note 1 and 2).
5. Dupilumab is prescribed by a dermatologist, allergist, pediatrician or clinical
immunologist, or in consultation with one of these specialists. (Please include the
consult note with the EAP application.)
Exclusion Criteria:
1. Dupilumab will not be funded if it is used in combination with phototherapy or any
immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor
treatment) for treatment of AD.
Notes:
1. For each treatment used, provide documentation of refractory disease and/or
intolerance (including a description of the adverse effect and severity of reaction). If a
patient is deemed to be ineligible or contraindicated to receive the treatment, provide
the reason(s) for their ineligibility.
111
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml Injection solution
2. An adequate trial for patients with AD who undergo therapy with phototherapy,
methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine is defined as
follows:
• For phototherapy: the typical duration would be considered 12 weeks (3 times per
week).
• For methotrexate: an adequate trial would be 10 mg to 20 mg per week for 12
weeks.
• For cyclosporine: an adequate trial would be 2.5 mg/kg to 5 mg/kg per day for 12
weeks.
• For mycophenolate mofetil: an adequate trial would be 1 g twice daily for 12
weeks.
• For azathioprine: an adequate trial would be 1.5 to 2.5 mg/kg/day for 12 weeks.
3. The concurrent use of dupilumab used in combination with other biologics used for
other conditions will be considered on a case-by-case basis.
Renewal Criteria:
First renewal:
Renewal of funding will be considered in patients with documentation of benefit from
treatment. Benefit from treatment is defined as a 75% or greater improvement from
baseline in the Eczema Area and Severity Index (EASI) score (EASI-75) within six months
of treatment initiation.
Subsequent renewals:
Subsequent renewal of funding will be considered in patient who maintain the 75% or
greater improvement in EASI-75 score response from baseline.
Duration of Approval for initial requests: 6 months
Duration of Approval for first and second renewal: 6 months
Duration of Approval for 3rd and subsequent renewals: 1 year
Recommended dose:
Adults: An initial dose of 600 mg followed by 300 mg every other week.
Refer to the product monograph for dosing in adolescents 17 year of age and younger.
112
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 111, record 69, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen,
300 mg/ 2mL prefilled syringe and prefilled pen
Effective Date: May 17, 2023
Initiation Criteria:
For the treatment of severe asthma in patients meeting the following criteria;
1. Patient is aged 6 years old or older; AND
2. Dupilumab is being used as an add-on maintenance therapy; AND
3. Patients 6 to 11 years of age with a type 2 or eosinophilic phenotype and a
documented blood eosinophil count equal to or greater than 150 cells/µL within the
past 12 months
OR
Patients 12 years of age or older with a type 2 or eosinophilic phenotype and a
documented blood eosinophil count equal to or greater than 150 cells/µL within the
past 12 months and/or has oral corticosteroid (OCS) dependent asthma; AND
60
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and
prefilled pen)
4. Asthma is inadequately controlled using optimal treatment.
i) For patients 6 to 11 years of age, this is defined as high dose inhaled
corticosteroids (ICS) (greater than or equal to 400 mcg fluticasone
priopionate daily or equivalent) alone OR medium- to high dose ICS plus 1
controller (e.g. a long-acting beta-agonists) AND experiencing at least one
severe exacerbation (defined as having been treated with a systemic
corticosteroid, hospitalized, or having visited an emergency department for
worsening asthma) in the past 12 months
ii) For patients 12 years and older, this is defined as using high dose ICS
(greater than or equal to 500 mcg of fluticasone propionate or equivalent
daily), and 1 or more additional asthma controller(s) (e.g., LABAs)1
5. Patient is not using any other biologics to treat asthma; AND
6. A baseline assessment of asthma symptom control using a validated asthma control
questionnaire must be completed prior to initiation of dupilumab treatment.
7. Request is submitted by a specialist in respirology, or allergy/clinical immunology, or
by a physician with expertise in the treatment of asthma, unless the request
confirms that the patient does not have access to such specialists, in which case the
request may be submitted by an authorized prescriber.
1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately
controlled if they have worsening of asthma resulting in administration of systemic
corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the
past 12 months
Renewal criteria:
Renewals will be considered on a case-by-case basis for patients 6 years of age or older
with type 2 or eosinophilic asthma who do not meet any of the following
discontinuation/stopping criteria:
61
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and
prefilled pen)
• Patient’s 12-month follow-up asthma control questionnaire score using the same
validated asthma control questionnaire completed at baseline does not show
improvement, such as a decrease of less than 0.5 points on the ACQ or an increase of
less than 3 points on the ACT;
• Patient’s subsequent asthma control questionnaire scores have not been maintained at
the score seen following the first 12-months of therapy;
• The number of clinically significant exacerbations defined as worsening of asthma
resulting in administration of systemic corticosteroids, an emergency room visit or
hospitalization, has increased within the previous 12 months.
Renewals will be considered on a case-by-case basis for patients 12 years of age or older
on maintenance treatment with OCS dependent asthma who do not meet any of the
following stopping criteria:
• there has been no decrease in the OCS dose in the first 12 months of treatment
• the reduction in the dose of OCS achieved after the first 12 months of treatment is not
maintained or improved subsequently
Approval duration of initial and renewals: 1 year
62
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 60, record 40, corpus 2025-01-01; name match only, not an eligibility decision
Patient pays: program not supplied; amount cannot be determined.
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95935
Health Canada: Marketed since 2018-02-06 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 300 MG/2ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d
Health Canada: Cancelled pre market since 2023-08-15 · brand DUPIXENT · ATC D11AH05 DUPILUMAB · form Solution · route Subcutaneous · ingredients DUPILUMAB 100 MG/0.67ML · company Sanofi-aventis canada inc · schedule Prescription, Schedule d
Source record
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22
DIN 02470365
Shortage status: resolved shortage (ended 2022-04-28); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470365
DIN 02492504
Shortage status: no shortage or discontinuation reported (checked 2026-10-06T03:13:29.198587+00:00); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02492504
DIN 02510049
Shortage status: no shortage or discontinuation reported (checked 2026-10-06T03:13:29.198587+00:00); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02510049
DIN 02524252
Shortage status: no shortage or discontinuation reported (checked 2026-10-06T03:13:29.198587+00:00); reports as of 2026-10-06T03:13:29.198587+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524252
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95935
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98251
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99930
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101328
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101530
Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95935, fetched 2026-10-05
Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98251, fetched 2026-10-05
Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99930, fetched 2026-10-05
Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101328, fetched 2026-10-05
Health Canada search source: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101530, fetched 2026-10-05
Prepare an Exceptional Access request
SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE
Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.
EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026
Posted turnaround and Telephone Request Service scope
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200mg/1.14mL, 300mg/2ml (Prefilled syringe and
prefilled pen)
Effective date: May 6, 2021
Updated: December 3, 2021 and December 1, 2022
Updated: April 28, 2023
Initiation Criteria
For the treatment of moderate to severe atopic dermatitis in patients meeting the all the
following criteria;
1. 12 years of age or older; AND
2. Diagnosed with moderate-to-severe atopic dermatitis (AD) by the Eczema Area and
Severity Index (EASI) score equal to or greater than 16 points and the Investigators
(Physician) Global Assessment score of 3 to 4; AND
3. Failure to maintain adequate control of their dermatitis with maximally tolerated medical
topical therapies for AD combined with phototherapy (where available); (Note 1 and 2)
AND
4. Failure to maintain adequate control of their dermatitis with maximally tolerated medical
topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators
(methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine). (Note 1 and 2).
5. Dupilumab is prescribed by a dermatologist, allergist, pediatrician or clinical
immunologist, or in consultation with one of these specialists. (Please include the
consult note with the EAP application.)
Exclusion Criteria:
1. Dupilumab will not be funded if it is used in combination with phototherapy or any
immunomodulatory drugs (including biologics (Note 3) or a Janus kinase [JAK] inhibitor
treatment) for treatment of AD.
Notes:
1. For each treatment used, provide documentation of refractory disease and/or
intolerance (including a description of the adverse effect and severity of reaction). If a
patient is deemed to be ineligible or contraindicated to receive the treatment, provide
the reason(s) for their ineligibility.
2. An adequate trial for patients with AD who undergo therapy with phototherapy,
methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine is defined as
follows:
• For phototherapy: the typical duration would be considered 12 weeks (3 times per
week).
• For methotrexate: an adequate trial would be 10 mg to 20 mg per week for 12
weeks.
• For cyclosporine: an adequate trial would be 2.5 mg/kg to 5 mg/kg per day for 12
weeks.
• For mycophenolate mofetil: an adequate trial would be 1 g twice daily for 12
weeks.
• For azathioprine: an adequate trial would be 1.5 to 2.5 mg/kg/day for 12 weeks.
3. The concurrent use of dupilumab used in combination with other biologics used for
other conditions will be considered on a case-by-case basis.
Renewal Criteria:
First renewal:
Renewal of funding will be considered in patients with documentation of benefit from
treatment. Benefit from treatment is defined as a 75% or greater improvement from
baseline in the Eczema Area and Severity Index (EASI) score (EASI-75) within six months
of treatment initiation.
Subsequent renewals:
Subsequent renewal of funding will be considered in patient who maintain the 75% or
greater improvement in EASI-75 score response from baseline.
Duration of Approval for initial requests: 6 months
Duration of Approval for first and second renewal: 6 months
Duration of Approval for 3rd and subsequent renewals: 1 year
Recommended dose:
Adults: An initial dose of 600 mg followed by 300 mg every other week.
Refer to the product monograph for dosing in adolescents 17 year of age and younger.
112
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.
Dupilumab (Dupixent)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Prepare answers: For the treatment of severe asthma in patients meeting the following criteria;
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/ 1.14 mL Prefilled syringe and prefilled pen,
300 mg/ 2mL prefilled syringe and prefilled pen
Effective Date: May 17, 2023
Initiation Criteria:
For the treatment of severe asthma in patients meeting the following criteria;
1. Patient is aged 6 years old or older; AND
2. Dupilumab is being used as an add-on maintenance therapy; AND
3. Patients 6 to 11 years of age with a type 2 or eosinophilic phenotype and a
documented blood eosinophil count equal to or greater than 150 cells/µL within the
past 12 months
OR
Patients 12 years of age or older with a type 2 or eosinophilic phenotype and a
documented blood eosinophil count equal to or greater than 150 cells/µL within the
past 12 months and/or has oral corticosteroid (OCS) dependent asthma; AND
60
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and
prefilled pen)
4. Asthma is inadequately controlled using optimal treatment.
i) For patients 6 to 11 years of age, this is defined as high dose inhaled
corticosteroids (ICS) (greater than or equal to 400 mcg fluticasone
priopionate daily or equivalent) alone OR medium- to high dose ICS plus 1
controller (e.g. a long-acting beta-agonists) AND experiencing at least one
severe exacerbation (defined as having been treated with a systemic
corticosteroid, hospitalized, or having visited an emergency department for
worsening asthma) in the past 12 months
ii) For patients 12 years and older, this is defined as using high dose ICS
(greater than or equal to 500 mcg of fluticasone propionate or equivalent
daily), and 1 or more additional asthma controller(s) (e.g., LABAs)1
5. Patient is not using any other biologics to treat asthma; AND
6. A baseline assessment of asthma symptom control using a validated asthma control
questionnaire must be completed prior to initiation of dupilumab treatment.
7. Request is submitted by a specialist in respirology, or allergy/clinical immunology, or
by a physician with expertise in the treatment of asthma, unless the request
confirms that the patient does not have access to such specialists, in which case the
request may be submitted by an authorized prescriber.
1Patients with type 2 or eosinophilic phenotypes are considered to be inadequately
controlled if they have worsening of asthma resulting in administration of systemic
corticosteroids for at least 3 days, or an emergency room visit, or hospitalization, in the
past 12 months
Renewal criteria:
Renewals will be considered on a case-by-case basis for patients 6 years of age or older
with type 2 or eosinophilic asthma who do not meet any of the following
discontinuation/stopping criteria:
61
Dupilumab
Brand(s): Dupixent
DOSAGE FORM/ STRENGTH: 200 mg/1.14 mL and 300mg/2mL (Prefilled syringe and
prefilled pen)
• Patient’s 12-month follow-up asthma control questionnaire score using the same
validated asthma control questionnaire completed at baseline does not show
improvement, such as a decrease of less than 0.5 points on the ACQ or an increase of
less than 3 points on the ACT;
• Patient’s subsequent asthma control questionnaire scores have not been maintained at
the score seen following the first 12-months of therapy;
• The number of clinically significant exacerbations defined as worsening of asthma
resulting in administration of systemic corticosteroids, an emergency room visit or
hospitalization, has increased within the previous 12 months.
Renewals will be considered on a case-by-case basis for patients 12 years of age or older
on maintenance treatment with OCS dependent asthma who do not meet any of the
following stopping criteria:
• there has been no decrease in the OCS dose in the first 12 months of treatment
• the reduction in the dose of OCS achieved after the first 12 months of treatment is not
maintained or improved subsequently
Approval duration of initial and renewals: 1 year
62
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.